NO20022531D0 - Vaccine for the prevention and treatment of Alzheimer's and amyloid-related diseases - Google Patents
Vaccine for the prevention and treatment of Alzheimer's and amyloid-related diseasesInfo
- Publication number
- NO20022531D0 NO20022531D0 NO20022531A NO20022531A NO20022531D0 NO 20022531 D0 NO20022531 D0 NO 20022531D0 NO 20022531 A NO20022531 A NO 20022531A NO 20022531 A NO20022531 A NO 20022531A NO 20022531 D0 NO20022531 D0 NO 20022531D0
- Authority
- NO
- Norway
- Prior art keywords
- amyloid
- alzheimer
- vaccine
- prevention
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16859499P | 1999-11-29 | 1999-11-29 | |
US72484200A | 2000-11-28 | 2000-11-28 | |
PCT/CA2000/001413 WO2001039796A2 (en) | 1999-11-29 | 2000-11-29 | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20022531D0 true NO20022531D0 (en) | 2002-05-28 |
NO20022531L NO20022531L (en) | 2002-07-12 |
Family
ID=26864284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20022531A NO20022531L (en) | 1999-11-29 | 2002-05-28 | Vaccine for the prevention and treatment of Alzheimer's and amyloid-related diseases |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1235587A2 (en) |
JP (1) | JP2004500354A (en) |
KR (2) | KR20080059676A (en) |
CN (1) | CN1433321A (en) |
AU (1) | AU784312B2 (en) |
BR (1) | BR0016022A (en) |
CA (1) | CA2388559A1 (en) |
HK (1) | HK1049279A1 (en) |
IL (1) | IL149924A0 (en) |
MX (1) | MXPA02005576A (en) |
NO (1) | NO20022531L (en) |
NZ (1) | NZ540564A (en) |
WO (1) | WO2001039796A2 (en) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997021728A1 (en) | 1995-12-12 | 1997-06-19 | Karolinska Innovations Ab | PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b) |
US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
US20020094335A1 (en) * | 1999-11-29 | 2002-07-18 | Robert Chalifour | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
KR100879810B1 (en) * | 2000-02-21 | 2009-01-22 | 하. 룬드벡 아크티에셀스카브 | Novel method for down-regulation of amyloid |
WO2002003911A2 (en) | 2000-07-07 | 2002-01-17 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
AU2007200047B2 (en) * | 2000-07-07 | 2009-11-26 | Bioarctic Neuroscience Ab | Prevention and treatment of Alzheimer's disease |
US20020115717A1 (en) * | 2000-07-25 | 2002-08-22 | Francine Gervais | Amyloid targeting imaging agents and uses thereof |
US7311893B2 (en) | 2000-07-25 | 2007-12-25 | Neurochem (International) Limited | Amyloid targeting imaging agents and uses thereof |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
AR038568A1 (en) * | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | ANTI-A BETA ANTIBODIES AND ITS USE |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
WO2004005318A2 (en) | 2002-07-03 | 2004-01-15 | Bio Science International, Inc. | Peptides comprising aromatic d-amino acids and methods of use |
DE10303974A1 (en) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
TWI306458B (en) | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
EP1658264A2 (en) * | 2003-06-23 | 2006-05-24 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
JP4696079B2 (en) * | 2003-12-17 | 2011-06-08 | ヤンセン アルツハイマー イミュノセラピー | Aβ immunogenic peptide carrier conjugate and method for producing the same |
SE0401601D0 (en) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
CA2590337C (en) | 2004-12-15 | 2017-07-11 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
EP1836161B1 (en) | 2004-12-22 | 2016-07-20 | BHI Limited Partnership | Methods and compositions for treating amyloid-related diseases |
KR100851035B1 (en) | 2005-08-23 | 2008-08-11 | 대한민국 | - - Pharmaceutical composition and composition for screening therapeutics to preventing and treating of -amyloid accumulation in brain comprising GCP-Glutamate carboxypeptidase- as an active ingredient method for screening using said composition |
US8067372B2 (en) | 2005-11-10 | 2011-11-29 | Alzheimer's Institute Of America, Inc. | Modulation of angiogenesis by A-beta peptide fragments |
RU2442793C2 (en) | 2005-11-30 | 2012-02-20 | Эбботт Лэборетриз | ANTISUBSTANCES AGAINST GLOBULOMER Aβ, THEIR ANTIGEN-BINDING PARTS, CORRESPONDING HYBRIDOMAS, NUCLEIC ACIDS, VECTORS, HOST CELLS, WAYS OF PRODUCTION OF MENTIONED ANTISUBSTANCES, COMPOSITIONS CONTAINING MENTIONED ANTISUBSTANCES, APPLICATION OF MENTIONED ANTISUBSTANCES AND WAYS OF APPLICATION OF MENTIONED ANTISUBSTANCES |
SG2014013437A (en) | 2005-11-30 | 2014-07-30 | Abbott Lab | Monoclonal antibodies and uses thereof |
CN101330923B (en) * | 2005-12-12 | 2015-01-07 | Ac免疫有限公司 | Therapeutic vaccine |
DOP2006000278A (en) | 2005-12-12 | 2007-07-15 | Hoffmann La Roche | GLYCOSILATION IN THE VARIABLE REGION |
NZ567888A (en) | 2006-03-23 | 2010-08-27 | Bioarctic Neuroscience Ab | Improved protofibril selective antibodies and the use thereof |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
KR20180043854A (en) * | 2006-07-14 | 2018-04-30 | 에이씨 이뮨 에스.에이. | Humanized antibody against amyloid beta |
MX2009000476A (en) | 2006-07-14 | 2009-01-28 | Ac Immune Sa | Humanized antibody against amyloid beta. |
PL2074145T3 (en) * | 2006-10-02 | 2017-11-30 | Ac Immune S.A. | Humanized antibody against amyloid beta |
DK3851447T3 (en) | 2006-10-12 | 2023-12-04 | Bellus Health Inc | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR THE ADMINISTRATION OF 3-AMINO-1-PROPANESULFOUS ACID |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
EP2149584B1 (en) | 2007-04-20 | 2017-12-13 | The Chemo-Sero-Therapeutic Research Institute | Method for enhancing immune response with peptide |
JP2010528583A (en) * | 2007-06-11 | 2010-08-26 | エーシー イミューン ソシエテ アノニム | Humanized antibody against amyloid β |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
ES2498040T3 (en) | 2007-07-27 | 2014-09-24 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases with humanized anti-beta antibodies |
WO2009048539A2 (en) | 2007-10-05 | 2009-04-16 | Genentech, Inc. | Monoclonal antibody |
JO3076B1 (en) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | Immunotherapy regimes dependent on apoe status |
WO2009143489A2 (en) * | 2008-05-22 | 2009-11-26 | Archer Pharmaceuticals, Inc. | Modulation of angiogenesis by a-beta peptide fragments |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
EP2273273A1 (en) * | 2009-07-11 | 2011-01-12 | Rheinische Friedrich-Wilhelms-Universität Bonn | Inhibitors of the nitration of amyloid ß peptides and their uses in the diagnosis and treatment of alzheimer's disease |
MX360403B (en) | 2010-04-15 | 2018-10-31 | Abbvie Inc | Amyloid-beta binding proteins. |
KR101713365B1 (en) | 2010-07-30 | 2017-03-08 | 에이씨 이뮨 에스.에이. | Safe and functional humanized anti beta-amyloid antibody |
JP6147665B2 (en) | 2010-08-14 | 2017-06-14 | アッヴィ・インコーポレイテッド | Amyloid beta-binding protein |
KR102564384B1 (en) | 2014-07-10 | 2023-08-07 | 바이오악틱 에이비 | Improved Aβ Protofibril Binding Antibodies |
PE20221007A1 (en) | 2015-06-24 | 2022-06-15 | Hoffmann La Roche | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH ENGINEERED AFFINITY |
AR106189A1 (en) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE |
CN114031689A (en) | 2015-10-02 | 2022-02-11 | 豪夫迈·罗氏有限公司 | Bispecific anti-human CD 20/human transferrin receptor antibodies and methods of use |
KR20180094876A (en) | 2015-11-09 | 2018-08-24 | 더 유니버시티 오브 브리티쉬 콜롬비아 | Amyloid beta epitopes and antibodies thereto |
KR20180085736A (en) | 2015-11-09 | 2018-07-27 | 더 유니버시티 오브 브리티쉬 콜롬비아 | Amyloid beta mid-region epitopes and structurally selective antibodies thereto |
US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1586584A1 (en) * | 1996-08-27 | 2005-10-19 | Praecis Pharmaceuticals Incorporated | Modulators of beta-amyloid peptide aggregation comprising D-amino acids |
NO314086B1 (en) * | 1998-05-08 | 2003-01-27 | Gemvax As | Peptides and pharmaceutical compositions containing them, nucleic acid sequences encoding such peptides, plasmids and virus vectors encompassing such DNA sequences and their use for the preparation of pharmaceutical preparations for |
JP2003503312A (en) * | 1999-05-05 | 2003-01-28 | ニューロシェム インコーポレイテッド | Stereoselective antigen fibril forming peptide and its peptidomimetic |
-
2000
- 2000-11-29 EP EP00981111A patent/EP1235587A2/en not_active Withdrawn
- 2000-11-29 JP JP2001541528A patent/JP2004500354A/en active Pending
- 2000-11-29 CN CN00816414A patent/CN1433321A/en active Pending
- 2000-11-29 IL IL14992400A patent/IL149924A0/en unknown
- 2000-11-29 WO PCT/CA2000/001413 patent/WO2001039796A2/en active Application Filing
- 2000-11-29 CA CA002388559A patent/CA2388559A1/en not_active Abandoned
- 2000-11-29 BR BR0016022-9A patent/BR0016022A/en not_active Application Discontinuation
- 2000-11-29 KR KR1020087013848A patent/KR20080059676A/en not_active Application Discontinuation
- 2000-11-29 KR KR1020027006845A patent/KR20020073341A/en not_active Application Discontinuation
- 2000-11-29 NZ NZ540564A patent/NZ540564A/en unknown
- 2000-11-29 AU AU18473/01A patent/AU784312B2/en not_active Ceased
- 2000-11-29 MX MXPA02005576A patent/MXPA02005576A/en not_active Application Discontinuation
-
2002
- 2002-05-28 NO NO20022531A patent/NO20022531L/en not_active Application Discontinuation
-
2003
- 2003-01-16 HK HK03100407.4A patent/HK1049279A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN1433321A (en) | 2003-07-30 |
KR20080059676A (en) | 2008-06-30 |
NO20022531L (en) | 2002-07-12 |
WO2001039796A3 (en) | 2001-12-06 |
MXPA02005576A (en) | 2002-12-13 |
BR0016022A (en) | 2002-08-06 |
WO2001039796A2 (en) | 2001-06-07 |
NZ540564A (en) | 2007-04-27 |
JP2004500354A (en) | 2004-01-08 |
HK1049279A1 (en) | 2003-05-09 |
AU1847301A (en) | 2001-06-12 |
EP1235587A2 (en) | 2002-09-04 |
AU784312B2 (en) | 2006-03-09 |
CA2388559A1 (en) | 2001-06-07 |
KR20020073341A (en) | 2002-09-23 |
IL149924A0 (en) | 2002-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20022531D0 (en) | Vaccine for the prevention and treatment of Alzheimer's and amyloid-related diseases | |
NO20014046D0 (en) | Gabapentin derivatives for the prevention and treatment of visceral pain | |
NO20015773D0 (en) | Prevention and treatment of amyloidogenic disease | |
LTPA2015001I1 (en) | Thioflavin derivatives and their use for diagnosis and therapy of Alzheimer's disease | |
IS5500A (en) | Medicinal preparations for the stimulation and treatment of gastrointestinal disorders and related diseases | |
NO994014D0 (en) | Arylsulfonamides and analogs thereof and their use in the treatment of neurodegenerative diseases | |
SI1303272T1 (en) | Benzothiazole derivatives for the treatment of alzheimer's disease and parkinson's disease | |
HUP0103654A2 (en) | Use of smilagenin and anzurogenin-d for production of pharmaceutical compositions for the treatment of alzheimer's disease | |
NO20004098L (en) | Methods and preparations for the treatment of macrophage-mediated disorders | |
NO972972D0 (en) | Compositions for the treatment of dermatological disorders and methods for their use | |
HUP0003852A3 (en) | Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias | |
NO20014314L (en) | Compositions and methods for the treatment of staphylococcal infection | |
NO20014617L (en) | 1-Arensulfonyl-2-aryl pyrrolidine and piperidine derivatives for the treatment of CNS diseases | |
NO20001869D0 (en) | Procedures for the treatment of Alzheimer's disease | |
DE69836209D1 (en) | PREVENTION AND TREATMENT OF HEPATOCELLULAR CANCER | |
NO20053341D0 (en) | Prevention and treatment of Alzheimer's disease. | |
NO20023448L (en) | Drug combination for the treatment of depression and related disorders including mirtazapine | |
NO20000771L (en) | Use of fanquinone for the treatment of Alzheimer's disease | |
NO20020784D0 (en) | Medication for the treatment of fractures | |
PT1152762E (en) | USE OF DEOXYGEGANIN IN THE TREATMENT OF ALZHEIMER'S DEMENTIA | |
AU5550800A (en) | Diagnosis and treatment of alzheimer's disease | |
NO20013651D0 (en) | Use of phosphorus inorganic compounds for the prophylactic and therapeutic treatment of infections | |
NO20012612L (en) | Isonipecotamides for the treatment of integrin-mediated diseases | |
NO20026148D0 (en) | Medicines for the prevention and treatment of neurodegenerative diseases | |
NO20022990L (en) | Method and composition for the treatment of pain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |